VI
VKTX icon

Vestcor Inc’s Viking Therapeutics VKTX Stock Holding History

Vestcor Inc’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,300
Closed -$656K – 1285
2024
Q4 		$656K Buy
16,300
+4,600
+39% +$262K 0.02% 583
2024
Q3 		$741K Buy
+11,700
New +$686K 0.02% 551
2024
Q2 		– Sell
-15,000
Closed -$1.23M – 1280
2024
Q1 		$1.23M Buy
+15,000
New +$667K 0.04% 373

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vestcor Inc's VKTX Position: Q1 2025 in Review

Vestcor Inc sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 16,300 shares — an estimated $656K sold.

Vestcor Inc first reported a position in VKTX in Q1 2024 and held it in 3 quarters. The position peaked at $1.23M in Q1 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Vestcor Inc reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Vestcor Inc sold 16,300 Viking Therapeutics shares in Q1 2025, an estimated $656K.
  • Vestcor Inc first reported a position in Viking Therapeutics in Q1 2024 and held it in 3 quarters.
  • Vestcor Inc's Viking Therapeutics position peaked at $1.23M in Q1 2024.
  • 373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Vestcor Inc's 13F filing for Q1 2025, filed 8 May 2025.